Lipoprotein(A) in familial hypercholesterolemia with proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutations

Circulation Journal

Volumn 80, Issue 2, 2016, Pages 512-518

  Tada, Hayato ^a   Kawashiri, Masa Aki ^a   Yoshida, Taiji ^a   Teramoto, Ryota ^a   Nohara, Atsushi ^a   Konno, Tetsuo ^a   Inazu, Akihiro ^b   Mabuchi, Hiroshi ^a   Yamagishi, Masakazu ^a   Hayashi, Kenshi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Familial hypercholesterolemia; Lipoprotein; Lipoprotein(a); Low density lipoprotein receptor; Proprotein convertase subtilisin kexin type 9 (PCSK9)

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN (PROTEIN); LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE;

ADULT; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GAIN OF FUNCTION MUTATION; GENE; GENETIC ANALYSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PCSK9 GENE; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; AGED; BLOOD; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; MUTATION;

ADULT; AGED; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); MALE; MIDDLE AGED; MUTATION; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RETROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES;

EID: 84955483356     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0999     Document Type: Article

References (39)

1. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 57U-66U.
2. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein(a): A unique risk factor for cardiovascular disease. Clin Lab Med 2006; 26: 751-772.
3. Hobbs HH, White AL. Lipoprotein(a): Intrigues and insights. Curr Opin Lipidol 1999; 10: 225-236.
4. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, et al. Lipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.
5. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-2199.
6. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423.
7. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-2528.
8. Qi Q, Workalemahu T, Zhang C, Hu FB, Qi L. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J 2012; 33: 325-334.
9. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: An analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation 2014; 129: 635-642.
10. Cenarro A, Puzo J, Ferrando J, Mateo-Gallego R, Bea AM, Calmarza P, et al. Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype. Metabolism 2014; 63: 365-371.
11. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: Potential sites for therapeutic targets. Metabolism 2013; 62: 479-491.
12. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 522-528.
13. Tziomalos K, Athyros VG, Wierzbicki AS, Mikhailidis DP. Lipoprotein a: Where are we now? Curr Opin Cardiol 2009; 24: 351-357.
14. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014; 129: 234-243.
15. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-1819.
16. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Familial hypercholesterolemia. J Atheroscler Thromb 2014; 21: 6-10.
17. Tada H, Kawashiri MA, Ikewaki K, Terao Y, Noguchi T, Nakanishi C, et al. Altered metabolism of low-density lipoprotein and verylow- density lipoprotein remnant in autosomal recessive hypercholesterolemia: Results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet 2012; 5: 35-41.
18. Tada H, Kawashiri MA, Takata M, Matsunami K, Imamura A, Matsuyama M, et al. Infantile cases of sitosterolemia with novel mutations in the ABCG5 gene: Extreme hypercholesterolemia is exacerbated by breastfeeding. JIMD Rep 2015; 21: 115-122.
19. Wu JH, Kao JT, Wen MS, Wu D. Coronary artery disease risk predicted by plasma concentrations of high-density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein B, and lipoprotein(a) in a general Chinese population. Clin Chem 1993; 39: 209-212.
20. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
21. Li PK, Chow KM, Matsuo S, Yang CW, Jha V, Becker G, et al. Asian chronic kidney disease best practice recommendations: Positional statements for early detection of chronic kidney disease from Asian Forum for Chronic Kidney Disease Initiatives (AFCKDI). Nephrology 2011; 16: 633-641.
22. Noguchi T, Katsuda S, Kawashiri MA, Tada H, Nohara A, Inazu A, et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 2010; 210: 166-172.
23. Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol 1992; 136: 441-449.
24. Berg K. A new serum type system in man: The LP system. Acta Pathol Microbiol Scand 1963; 59: 369-382.
25. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010; 31: 2844-2853.
26. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 2008; 117: 176-184.
27. Nguyen SV, Nakamura T, Kugiyama K. High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome. Circ J 2014; 78: 2492-2500.
28. Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol 2015; 65: 2267-2275.
29. Mori K, Ishida T, Yasuda T, Hasokawa M, Monguchi T, Sasaki M, et al. Serum trans-fatty acid concentration is elevated in young patients with coronary artery disease in Japan. Circ J 2015; 79: 2017-2025.
30. Higuma T, Abe N, Tateyama S, Endo T, Shibutani S, Yokoyama H, et al. Plasma soluble lectin-like oxidized low-density lipoprotein receptor-1 as a novel prognostic biomarker in patients with ST-segment elevation acute myocardial infarction. Circ J 2015; 79: 641-648.
31. Izawa H, Amano T. Plasma microRNA-100 as a biomarker of coronary plaque vulnerability: A new generation of biomarker for developing acute coronary syndrome. Circ J 2015; 79: 303-304.
32. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015; 290: 11649-11662.
33. Millar JS, Maugeais C, Ikewaki K, Kolansky DM, Barrett PH, Budreck EC, et al. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol 2005; 25: 560-565.
34. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56: 1252-1260.
35. Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015; 313: 1029-1036.
36. Nair DR, Papadakis JA, Jagroop IA, Mikhailidis DP, Winder AF. Statins and fibrinogen. Lancet 1998; 351: 1430.
37. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, et al. High-dose atorvastatin reduces total plasma levels ofoxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110: 1406-1412.
38. Choi SH, Chae A, Miller E, Messig M, Ntanios F, DeMaria AN, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: Volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol 2008; 52: 24-32.
39. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000; 46: 1956-1967.